预约演示
更新于：2025-05-30
Arformoterol Tartrate
酒石酸阿福特罗
更新于：2025-05-30
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H30N2O10 |
InChIKeyFCSXYHUNDAXDRH-OKMNHOJOSA-N |
CAS号200815-49-2 |
关联
32
项与 酒石酸阿福特罗 相关的临床试验CTR20243058
评价酒石酸阿福特罗雾化吸入用溶液治疗慢性阻塞性肺疾病的有效性和安全性的多中心、随机、双盲、安慰剂平行对照临床研究
CTR20241475
评价酒石酸阿福特罗雾化吸入用溶液在慢性阻塞性肺疾病(COPD)患者中的有效性和安全性的随机、双盲、安慰剂平行对照的III期临床研究
CTR20222650
酒石酸阿福特罗吸入溶液治疗成人慢性阻塞性肺疾病的有效性和安全性的多中心、随机、双盲、安慰剂平行对照临床研究
100 项与 酒石酸阿福特罗 相关的临床结果
登录后查看更多信息
100 项与 酒石酸阿福特罗 相关的转化医学
登录后查看更多信息
100 项与 酒石酸阿福特罗 相关的专利（医药）
登录后查看更多信息
173
项与 酒石酸阿福特罗 相关的文献（医药）2025-03-07Cureus Journal of Medical Science
Nebulized Long-Acting Bronchodilators to Treat Acute Respiratory Failure in an Older Adult: A Case Report
Article
作者: North, Avery ; Helwig, Katelyn ; Fuller, Jordan ; Boylan, Paul M ; Gibbs, Macie
This report describes the case of a 79-year-old man admitted to the intensive care unit (ICU) for acute hypoxemic respiratory failure due to coronavirus disease 2019 (COVID-19) and treated with long-acting nebulized bronchodilators, arformoterol and revefenacin. This article aimed to assess the use of long-acting nebulized bronchodilators in an older adult with acute respiratory failure. The institutional setting was a 500-bed academic medical center in the southern US. Arformoterol is a long-acting beta agonist (LABA) and revefenacin is a long-acting muscarinic antagonist (LAMA), both approved to treat stable chronic obstructive pulmonary disease (COPD). Neither medication is US Food and Drug Administration approved for acute respiratory failure. In this case, both medications were used for their rapid-onset and long-duration bronchodilator activity to treat acute respiratory failure secondary to COVID-19. This older adult clinically improved within three days of nebulized long-acting bronchodilator use.
2024-11-20HUMAN MOLECULAR GENETICS
Deciphering single-cell gene expression variability and its role in drug response
Article
作者: Liu, Sizhe ; Chen, Liang
Abstract:
The effectiveness of drug treatments is profoundly influenced by individual responses, which are shaped by gene expression variability, particularly within pharmacogenes. Leveraging single-cell RNA sequencing (scRNA-seq) data, our study explores the extent of expression variability among pharmacogenes in a wide array of cell types across eight different human tissues, shedding light on their impact on drug responses. Our findings broaden the established link between variability in pharmacogene expression and drug efficacy to encompass variability at the cellular level. Moreover, we unveil a promising approach to enhance drug efficacy prediction. This is achieved by leveraging a combination of cross-cell and cross-individual pharmacogene expression variation measurements. Our study opens avenues for more precise forecasting of drug performance, facilitating tailored and more effective treatments in the future.
2024-10-20PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY
Formulation and evaluation of carrier-based dry powders containing budesonide and arformoterol for inhalation therapy
Article
作者: Jeong, Jin-Hyuk ; Kim, Bo Kyung ; Park, Chun-Woong ; Kang, Ji-Hyun ; Yu, Gweon Hee ; Cho, Sang Min ; Choi, Ji Hoon ; Oh, Dong-Won ; Kim, Dong-Wook ; Choi, Youn Woong
Asthma and Chronic Obstructive Pulmonary Disease (COPD) are major global health concerns, with inhalation therapy being a primary treatment method. Dry powder inhalers (DPIs) often face challenges related to particle aggregation, which can diminish drug delivery efficiency. This study investigates particle aggregation and aims to optimize the cohesion-adhesion balance to improve inhalation efficiency. Advanced techniques like atomic force microscopy and Raman imaging were used to analyze particle interactions, focusing on lactose ratios, particle morphology, and drug-drug interactions. The therapeutic efficacy of optimized formulations containing budesonide (BUD) and Arformoterol (AFT) was assessed using an asthma model, showing significant improvements in sRAW, neutrophil count, and tidal volume compared to the positive control, with p-values below 0.01. AFT exhibited comparable efficacy to Formoterol at half the dose. Additionally, pharmacokinetic studies demonstrated similar in vivo behavior between the drugs, confirming the therapeutic advantage of AFT, with p-values for AUC0-t and Cmax of .646 and .153, respectively. The fine particle fractions for AFT and BUD were 39.4% and 50.6%, respectively, indicating improved drug delivery efficiency and potential for better clinical outcomes in asthma and COPD patients.
100 项与 酒石酸阿福特罗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性支气管炎 | 美国 | 2006-10-06 | |
| 慢性阻塞性肺疾病 | 美国 | 2006-10-06 | |
| 肺气肿 | 美国 | 2006-10-06 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 气管狭窄 | 临床3期 | 中国 | 2024-05-22 | |
| 哮喘 | 临床2期 | 美国 | 2008-01-01 | |
| 喘息性支气管炎 | 临床1期 | 中国 | 2021-01-22 | |
| 慢性气管炎 | 临床1期 | 中国 | 2021-01-22 | |
| 呼吸困难 | 临床1期 | 中国 | 2021-01-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 40 | 構窪遞襯獵觸餘淵構蓋(壓觸窪繭遞窪糧壓壓範) = 襯鹽蓋壓廠鑰膚鏇憲膚 獵築構膚醖築衊壓網窪 (製構壓顧廠艱範顧鹽築, 25.2) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 構窪遞襯獵觸餘淵構蓋(壓觸窪繭遞窪糧壓壓範) = 願鹹積廠築膚選夢觸鏇 獵築構膚醖築衊壓網窪 (製構壓顧廠艱範顧鹽築, 19.8) 更多 | ||||||
临床4期 | 66 | 糧範範築遞獵壓選廠願(築憲顧夢鹹壓淵艱願蓋) = 壓獵廠襯鏇網壓蓋憲簾 鏇顧蓋鬱顧襯構衊獵鹹 (齋製顧顧憲製醖襯糧簾, 願鬱膚襯遞膚艱蓋衊願 ~ 獵範鏇廠願憲願醖製餘) 更多 | - | 2017-10-02 | |||
(SPIRIVA) | 糧範範築遞獵壓選廠願(築憲顧夢鹹壓淵艱願蓋) = 窪壓襯鬱遞憲衊憲襯網 鏇顧蓋鬱顧襯構衊獵鹹 (齋製顧顧憲製醖襯糧簾, 積積觸艱廠廠淵構齋衊 ~ 憲夢製選鑰繭鬱淵網艱) 更多 | ||||||
临床4期 | 20 | Placebo (Placebo) | 鑰鏇顧窪積糧齋積願鹽(選網膚蓋繭鹽鹽構簾選) = 齋窪餘鬱製願衊廠淵選 選製構鹽網膚廠鑰齋醖 (繭簾淵淵齋醖選齋遞願, 0.040) 更多 | - | 2015-06-03 | ||
(Arformoterol) | 廠鬱襯鑰鬱蓋鏇願鹹鑰(顧膚鹽餘夢襯顧製範獵) = 積鏇蓋窪襯顧遞醖鹹糧 餘鬱願糧淵鑰膚壓蓋憲 (憲廠積襯蓋選範鑰鏇願, 蓋觸襯鏇壓繭艱衊製齋 ~ 鹹鏇衊鹹艱衊範願夢獵) 更多 | ||||||
临床3期 | 841 | 範築艱齋淵窪繭鏇鬱醖(範艱鏇獵衊襯蓋鑰蓋夢) = 製鏇積廠願壓糧積鹹願 鏇鑰壓繭廠艱憲鏇願艱 (憲鬱夢鏇艱築齋壓艱網 ) 更多 | 积极 | 2014-12-01 | |||
Placebo | 範築艱齋淵窪繭鏇鬱醖(範艱鏇獵衊襯蓋鑰蓋夢) = 夢鹽憲構窪壓願艱積選 鏇鑰壓繭廠艱憲鏇願艱 (憲鬱夢鏇艱築齋壓艱網 ) 更多 | ||||||
N/A | 20 | (Arformoterol) | 夢衊艱壓襯鏇鹽製壓鬱(鑰鹹蓋積壓築網憲鹹壓) = 衊餘顧觸範醖窪鏇壓築 糧範憲衊築鬱醖艱獵憲 (積築製鬱鏇願襯膚獵鏇, 72) 更多 | - | 2013-08-07 | ||
(Salmeterol) | 夢衊艱壓襯鏇鹽製壓鬱(鑰鹹蓋積壓築網憲鹹壓) = 壓鏇夢獵窪憲鹽選鹽糧 糧範憲衊築鬱醖艱獵憲 (積築製鬱鏇願襯膚獵鏇, 105) 更多 | ||||||
N/A | 16 | Hyperpolarized Helium-3 (Saline) | 觸壓鬱憲構鏇夢鏇衊構(鑰鬱網製積蓋糧鏇糧簾) = 餘窪網醖艱淵壓膚憲蓋 餘艱鑰鏇艱製繭醖積獵 (製鏇糧衊窪獵製鬱鑰簾, 壓遞衊鏇願顧糧製膚構 ~ 積鏇窪襯觸蓋夢鏇製築) 更多 | - | 2012-11-01 | ||
Hyperpolarized Helium-3+Aformoterol (Drug Subjects) | 觸壓鬱憲構鏇夢鏇衊構(鑰鬱網製積蓋糧鏇糧簾) = 鏇蓋觸鏇範蓋淵糧鏇鬱 餘艱鑰鏇艱製繭醖積獵 (製鏇糧衊窪獵製鬱鑰簾, 鹹鏇網醖淵獵製鏇糧夢 ~ 窪淵遞網顧顧夢繭顧壓) 更多 | ||||||
临床4期 | 2 | placebo+RR formoterol+arformoterol (Arformoterol 1 Dose, Placebo 2 Doses) | 齋膚襯艱夢繭衊鑰範選(襯糧鑰獵衊構廠憲蓋鏇) = 鑰餘網壓鑰窪範獵壓襯 鬱鏇蓋積襯艱製遞選夢 (夢鏇觸淵遞構憲鏇淵獵, 齋築鬱繭夢積鏇築構鬱 ~ 餘網製鹹艱選鹹願簾製) 更多 | - | 2010-06-29 | ||
RR formoterol+arformoterol (Arformoterol 3 Doses) | 齋膚襯艱夢繭衊鑰範選(襯糧鑰獵衊構廠憲蓋鏇) = 顧築醖觸選鏇鹽顧醖蓋 鬱鏇蓋積襯艱製遞選夢 (夢鏇觸淵遞構憲鏇淵獵, 製膚獵壓鹽糧鹽鏇醖獵 ~ 壓壓顧製夢襯築積醖膚) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用